Measuring Tumor Mutational Burden Using Whole-Exome Sequencing

Pages: 63 - 91
Published: Sep 10, 2019
Abstract
Cancer immunotherapy, particularly a class of antibodies targeting the CTLA4 and PD-1/PD-L1 negative regulators of immune response (collectively called the immune checkpoint), is one of the most promising approaches for cancer treatment and the use of immune checkpoint inhibitors (ICI) has demonstrated remarkable success in several types of cancer. In studies of unselected patient populations, it was shown that melanoma, non small cell lung...
Paper Details
Title
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing
Published Date
Sep 10, 2019
Pages
63 - 91
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.